Nakano Y, Monden M, Valdivia L A, Gotoh M, Tono T, Mori T
Department of Surgery II, Osaka University Medical School, Japan.
Surgery. 1992 Jun;111(6):668-76.
Antigen pretreatment through the oral or intraportal route has been reported to suppress antibody formation or delayed-type hypersensitivity (DTH) response to the same antigens. However, this effect on allografted organs has not been well studied. In this study we evaluated the efficacy for suppression of antibody formation and DTH response to the allogeneic antigens and tried to prolong liver allograft survival in rats. Male ACI (RT1a) rats were used as donors and male BUF (RT1b) rats as recipients. Intraportal or intravenous injection of spleen cells (SPCs) (5 x 10(7)) was performed through the mesenteric vein or the tail vein, respectively. The anti-ACI DTH response was tested by ear challenge of ACI SPCs. Cytotoxic antibody was assessed by complement-dependent cytotoxicity assay. ACI rat liver was transplanted orthotopically to BUF rat by the cuff technique 10 days after SPC injection. Cytotoxic antibody titer rose to X2(6) to X2(8) at 7 to 10 days after intravenous injection of SPCs. However, intraportal injection of the cells rarely caused a rise in antibody titer and even strongly suppressed subsequent antibody formation induced by intravenous injection when given 10 days before. The DTH response was also suppressed by intraportal injection of SPCs, with a mean value of 0.18 +/- 0.13 mm versus 0.67 +/- 0.19 mm for controls or 0.46 +/- 0.04 mm with intravenous injection. Liver-allografted rats died between 9 and 11 days, averaging 10.1 +/- 0.7 days in the control group. All seven transplants injected intraportally with donor SPCs survived more than 100 days, whereas six of eight rats injected intravenously with donor SPCs died of bleeding from the surface of the liver grafts within 12 hours after grafting, with signs similar to those of hyperacute rejection. Four of five rats injected intraportally with F344 (third-party) SPCs died of acute rejection in the same way the control rats died. The liver allograft-bearing rats had permanently accepted ACI skin grafts when tested 60 days after liver transplantation but rejected F344 skin grafts in the normal fashion. Intraportal injection of donor SPCs markedly suppressed the antibody formation, as well as the DTH response, and completely blocked liver allograft rejection. Moreover, the liver allograft-bearing rats proved to be fully tolerant of the donor antigen. This method might be a promising modality for inducing donor-specific tolerance in liver transplantation.
据报道,通过口服或门静脉内途径进行抗原预处理可抑制对相同抗原的抗体形成或迟发型超敏反应(DTH)。然而,这种对同种异体移植器官的作用尚未得到充分研究。在本研究中,我们评估了抑制对同种异体抗原的抗体形成和DTH反应的效果,并试图延长大鼠肝移植的存活时间。雄性ACI(RT1a)大鼠用作供体,雄性BUF(RT1b)大鼠用作受体。分别通过肠系膜静脉或尾静脉进行门静脉内或静脉内注射脾细胞(SPCs)(5×10⁷)。通过用ACI SPCs进行耳部攻击来测试抗ACI DTH反应。通过补体依赖性细胞毒性测定评估细胞毒性抗体。在注射SPCs 10天后,通过套管技术将ACI大鼠肝脏原位移植到BUF大鼠体内。静脉注射SPCs后7至10天,细胞毒性抗体滴度升至X2⁶至X2⁸。然而,门静脉内注射细胞很少导致抗体滴度升高,并且在10天前给予时甚至强烈抑制随后由静脉注射诱导的抗体形成。门静脉内注射SPCs也抑制了DTH反应,平均值为0.18±0.13毫米,而对照组为0.67±0.19毫米,静脉注射组为0.46±0.04毫米。肝移植大鼠在9至11天之间死亡,对照组平均为10.1±0.7天。所有七只门静脉内注射供体SPCs的移植大鼠存活超过100天,而八只静脉注射供体SPCs的大鼠中有六只在移植后12小时内死于肝移植表面出血,症状与超急性排斥反应相似。五只门静脉内注射F344(第三方)SPCs的大鼠中有四只以与对照大鼠相同的方式死于急性排斥反应。肝移植大鼠在肝移植后60天进行测试时永久接受了ACI皮肤移植,但以正常方式排斥了F344皮肤移植。门静脉内注射供体SPCs显著抑制了抗体形成以及DTH反应,并完全阻断了肝移植排斥反应。此外,肝移植大鼠被证明对供体抗原具有完全耐受性。这种方法可能是诱导肝移植中供体特异性耐受的一种有前途的方式。